Forte Biosciences (FBRX) Change in Accured Expenses (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Change in Accured Expenses data on file, last reported at $439000.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 74.01% year-over-year to $439000.0 in Q1 2026; TTM through Mar 2026 was $7.2 million, a 198.87% increase from a year earlier, with the FY2025 full-year figure at $8.4 million, up 7608.26% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $439000.0, down from $3.3 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for FBRX reached as high as $3.6 million in Q3 2025 and fell as low as -$1.2 million in Q3 2023.
• Historically, Change in Accured Expenses has averaged $608823.5 across 5 years, with a median of $287000.0 in 2022.
• Across the five-year window, Change in Accured Expenses sank 955.2% in 2024 and surged 960.66% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $924000.0 in 2022, then tumbled by 86.47% to $125000.0 in 2023, then sank by 955.2% to -$1.1 million in 2024, then jumped by 405.14% to $3.3 million in 2025, then slumped by 86.54% to $439000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $439000.0 in Q1 2026, $3.3 million in Q4 2025, and $3.6 million in Q3 2025.